公开(公告)号：US10849823B2

公开(公告)日：2020-12-01

申请号：US16044714

申请日：2018-07-25

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Christine P. Janson ,  Ethan B. Jacoby ,  Frederick Carel Steinmann ,  Nikhil Gandhi ,  Chad Presher

IPC: A61J1/05 ,  B65D21/02 ,  B65D25/10 ,  B65D43/16 ,  A61M5/00 ,  A61J1/20

Abstract: Device containers, such as therapeutic kit containers, are disclosed. In one embodiment, a device container includes a first member configured to releasably hold a syringe barrel, a second member configured to releasably hold a vial, wherein the second member is coupled to the first member by a first hinge, and a third member configured to releasably hold a vial adapter, wherein the third member is coupled to the second member by a second hinge.

公开(公告)号：US10786554B2

公开(公告)日：2020-09-29

申请号：US15455043

申请日：2017-03-09

Applicant: Bioverativ Therapeutics Inc.

Inventor： Kevin Maloney ,  Daniel Gage ,  Ahmad Abdul-Fattah

IPC: A61K38/37 ,  C07K14/755 ,  C07K16/28

Abstract: The present invention provides a formulation of a Factor VIII polypeptide, e.g., FVIII-Fc, and methods of using the same. The FVIII polypeptide can be a recombinant FVIII protein, a short-acting FVIII protein, or a long-acting FVIII protein. The pharmaceutical formulation comprising a FVIII polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia.

公开(公告)号：US20200261554A1

公开(公告)日：2020-08-20

申请号：US16773634

申请日：2020-01-27

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Mark BRADER

IPC: A61K38/48 ,  A61K9/19 ,  A61M5/19 ,  A61M5/178 ,  A61M5/158 ,  A61K47/26 ,  A61K47/22 ,  A61K47/10 ,  A61K47/02 ,  A61K9/00

Abstract: The present invention provides formulations comprising a Factor IX-FcRn Binding Partner (FIXFBP) polypeptide, and methods of administering FIXFBP.

公开(公告)号：US10745680B2

公开(公告)日：2020-08-18

申请号：US15750119

申请日：2016-08-03

Applicant: Bioverativ Therapeutics Inc.

Inventor： Zhiqian Liu ,  Arjan Van Der Flier ,  David R. Light ,  Ekta Seth Chhabra ,  Tongyao Liu ,  Robert T. Peters ,  John Kulman ,  Ayman Ismail

IPC: C12N9/64 ,  C07K14/745 ,  A61K9/00 ,  A61P7/04 ,  C07K14/00 ,  A61K38/00

Abstract: The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins.

公开(公告)号：US20200087379A1

公开(公告)日：2020-03-19

申请号：US16521789

申请日：2019-07-25

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Volker Schellenberger ,  Pei-Yun Chang ,  Fatbardha Varfaj ,  Sheng Ding ,  Joshua Silverman ,  Chia-wei Wang ,  Benjamin Spink ,  Willem P. Stemmer ,  Nathan Geething ,  John Kulman ,  Tongyao Liu ,  Garabet G. Toby ,  Haiyan Jiang ,  Robert Peters ,  Deping Wang ,  Baisong Mei

IPC: C07K14/755

Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.

公开(公告)号：US20200048327A1

公开(公告)日：2020-02-13

申请号：US16516816

申请日：2019-07-19

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： John KULMAN

IPC: C07K14/755 ,  C07K14/59 ,  C07K14/79 ,  A61K38/37 ,  A61K35/14 ,  C07K14/00 ,  C07K14/435 ,  C07K14/705 ,  C07K14/76

Abstract: Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins with heterologous moieties inserted into flexible permissive loops located in the Factor VIII A domains, while retaining the procoagulant activity of Factor VIII.

公开(公告)号：US10548954B2

公开(公告)日：2020-02-04

申请号：US16271689

申请日：2019-02-08

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Glenn Pierce ,  Samantha Truex ,  Robert T. Peters ,  Haiyan Jiang

IPC: A61K38/36 ,  A61K38/48 ,  A61K47/64 ,  A61K39/395 ,  C12N9/96 ,  A61K38/38 ,  C07K16/18 ,  C12N9/64 ,  C07K14/76 ,  A61K9/00 ,  A61P7/04

Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

公开(公告)号：US10548953B2

公开(公告)日：2020-02-04

申请号：US14912047

申请日：2014-08-14

Applicant: Bioverativ Therapeutics Inc.

Inventor： Tongyao Liu ,  Pei-Yun Chang ,  John Kulman ,  Volker Schellenberger ,  Haiyan Jiang ,  Robert T. Peters ,  Ekta Seth Chhabra

IPC: A61K38/37 ,  A61K9/00 ,  C07K14/00 ,  C07K14/755 ,  C12N15/85 ,  A61K48/00

Abstract: The present invention provides chimeric proteins comprising a Factor VIII (FVIII) polypeptide and XTEN polypeptides. The FVIII polypeptide can have a reduced affinity for von Willebrand Factor (VWF). XTEN polypeptides of appropriate sizes are inserted into the FVIII polypeptide at particular locations in order to extend the half-life of the FVIII polypeptide. The invention also includes nucleotides, vectors, host cells, and methods of using the chimeric proteins, e.g., to treat bleeding diseases and disorders.

公开(公告)号：US10513551B2

公开(公告)日：2019-12-24

申请号：US15465319

申请日：2017-03-21

Applicant: Bioverativ Therapeutics Inc.

Inventor： Robert T. Peters ,  Adam R. Mezo ,  Daniel S. Rivera ,  Alan J. Bitonti ,  Susan C. Low

IPC: C07K19/00 ,  A61K39/00 ,  C07K14/755 ,  C07K14/475 ,  C07K14/505 ,  C07K14/555 ,  C07K14/56 ,  C07K14/565 ,  C07K14/745 ,  C07K16/00 ,  C12N9/64 ,  C12N9/96 ,  A61K47/60 ,  A61K47/68 ,  C07K14/59 ,  C07K14/61 ,  C07K14/705 ,  A61K47/64 ,  A61K38/00

Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

公开(公告)号：US20190381149A1

公开(公告)日：2019-12-19

申请号：US16463748

申请日：2017-12-01

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Jennifer DUMONT ,  Nisha JAIN ,  Desilu GLAZEBROOK

IPC: A61K38/37 ,  A61P19/02 ,  A61P7/04 ,  A61K38/48

Abstract: The present disclosure provides methods treating reversible hemophilic arthropathy of a joint in a human having hemophilia comprising administering to the human an effective amount of a chimeric protein or composition comprising a clotting factor and an Fc region.